PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200
Debt
Debt-to-Equity Ratio1.29
Current Ratio0.83
Quick Ratio0.83
Price-To-Earnings
Trailing P/E Ratio29.90
Forward P/E Ratio25.12
P/E Growth1.47
Sales & Book Value
Annual Sales$2.26 billion
Price / Sales2.71
Cash Flow$4.7115 per share
Price / Cash20.31
Book Value$14.78 per share
Price / Book6.47
Profitability
EPS (Most Recent Fiscal Year)$3.20
Net Income$86.92 million
Net Margins4.07%
Return on Equity23.06%
Return on Assets6.84%
Miscellaneous
Employees15,800
Outstanding Shares64,080,000
PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings results on Wednesday, April, 25th. The medical research company reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.84 by $0.01. The medical research company had revenue of $701.80 million for the quarter, compared to analysts' expectations of $694.73 million. PRA Health Sciences had a net margin of 4.07% and a return on equity of 23.06%. The business's quarterly revenue was up 43.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 earnings per share. View PRA Health Sciences' Earnings History.
When is PRA Health Sciences' next earnings date?
What guidance has PRA Health Sciences issued on next quarter's earnings?
PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.
What price target have analysts set for PRAH?
11 equities research analysts have issued 1 year target prices for PRA Health Sciences' stock. Their forecasts range from $86.00 to $104.00. On average, they anticipate PRA Health Sciences' stock price to reach $95.1818 in the next year. View Analyst Ratings for PRA Health Sciences.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Viralytics (VRACY).
Who are PRA Health Sciences' key executives?
PRA Health Sciences' management team includes the folowing people:
- Mr. Colin Shannon, Chairman, CEO & Pres (Age 59)
- Ms. Linda Baddour, Exec. VP, CFO, Corp. Sec. & Principal Accounting Officer (Age 60)
- Dr. David W. Dockhorn, Exec. VP & Corp. Compliance Officer (Age 57)
- Michael J. Bonello, Sr. VP of Accounting and Corp. Controller
- Christine Rogers, Director of PR & Corp. Communications
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Has PRA Health Sciences been receiving favorable news coverage?
Media stories about PRAH stock have trended somewhat negative on Friday, according to Accern Sentiment. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PRA Health Sciences earned a coverage optimism score of -0.06 on Accern's scale. They also gave media stories about the medical research company an impact score of 44.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are PRA Health Sciences' major shareholders?
PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.66%), Eagle Asset Management Inc. (1.92%), Wells Fargo & Company MN (1.64%), Northern Trust Corp (0.97%), Vaughan Nelson Investment Management L.P. (0.80%) and OppenheimerFunds Inc. (0.79%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Which major investors are selling PRA Health Sciences stock?
PRAH stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Federated Investors Inc. PA, Hood River Capital Management LLC, BlackRock Inc., Rock Springs Capital Management LP, American Century Companies Inc. and King Luther Capital Management Corp. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.
Which major investors are buying PRA Health Sciences stock?
PRAH stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Clinton Group Inc., Stephens Investment Management Group LLC, OppenheimerFunds Inc., Prudential Financial Inc. and California Public Employees Retirement System. View Insider Buying and Selling for PRA Health Sciences.
How do I buy shares of PRA Health Sciences?
Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PRA Health Sciences' stock price today?
One share of PRAH stock can currently be purchased for approximately $95.69.
How big of a company is PRA Health Sciences?
PRA Health Sciences has a market capitalization of $6.11 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.
How can I contact PRA Health Sciences?
PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]
MarketBeat Community Rating for PRA Health Sciences (PRAH)
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
